The race to an orally active Factor Xa inhibitor: recent advances.
Curr Opin Drug Discov Devel
; 7(4): 460-9, 2004 Jul.
Article
in En
| MEDLINE
| ID: mdl-15338955
ABSTRACT
Factor Xa (fXa) is a key enzyme in the coagulation cascade and an essential component of the prothrombinase complex, which activates prothrombin to thrombin, leading to fibrin clot formation. In the search for a more effective and safer orally active anticoagulant, fXa has emerged as a major target for potential therapeutic applications in the treatment and prevention of thrombosis. This review focuses on recent advances in the chemistry of drug design and lead optimization of orally bioavailable fXa inhibitors. Many of these orally active fXa inhibitors are currently in clinical trials and are anticipated to change the landscape of thrombosis therapy.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Antithrombin III
/
Administration, Oral
Type of study:
Prognostic_studies
Aspects:
Determinantes_sociais_saude
Limits:
Animals
/
Humans
Language:
En
Journal:
Curr Opin Drug Discov Devel
Journal subject:
FARMACOLOGIA
/
TERAPIA POR MEDICAMENTOS
Year:
2004
Document type:
Article
Affiliation country:
United States